BioCrea GmbH develops drugs to treat debilitating central nervous system diseases. The company primarily focuses on developing programs focusing on neurological and psychotic disorders.
It is in collaboration with the Department of Neurology at Dresden University of Technology to discover new treatments for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/biocrea-gmbh” connections=”true” suffix=””]
BioCrea discovery platform projects include NMDA-receptor positive & negative allosteric modulator (PAM & NAM) to treat depression and schizophrenia, and selective GABA receptor modulators to treat epilepsy and autism spectrum disorders.
In Feb 2012, entered into an asset purchase agreement with Boehringer Ingelheim, under which it granted worldwide development & commercialization rights of certain PDE platform research programs, including its PDE2 inhibitor, BCA909.